The Oncology Institute Announces CFO Transition
The Oncology Institute (NASDAQ: TOI) has announced a CFO transition. Mihir Shah, the current CFO, will leave the organization on October 14, 2024. Rob Carter, Senior Vice President of Finance, will be promoted to Chief Financial Officer. Carter, who joined TOI in 2021, brings over a decade of finance leadership experience from notable healthcare institutions.
CEO Dr. Daniel Virnich expressed excitement about Carter's promotion, citing his experience in oncology and large health systems. Virnich also thanked Shah for his contributions, including leading TOI through its early years as a public company and improving capabilities in reporting, compliance, and analytics.
Carter stated his honor in becoming TOI's next CFO and his belief in the company's future growth and innovation. TOI, founded in 2007, delivers specialized, value-based cancer care in community settings, serving over 1.8 million patients with 126 employed clinicians and more than 700 teammates across 70+ clinic locations.
L'Istituto di Oncologia (NASDAQ: TOI) ha annunciato un cambio di CFO. Mihir Shah, l'attuale CFO, lascerà l'organizzazione il 14 ottobre 2024. Rob Carter, Vicepresidente Senior delle Finanze, sarà promosso a Chief Financial Officer. Carter, che è entrato a far parte di TOI nel 2021, porta con sé oltre un decennio di esperienza nella leadership finanziaria in prestigiose istituzioni sanitarie.
Il CEO Dr. Daniel Virnich ha espresso entusiasmo per la promozione di Carter, citando la sua esperienza in oncologia e all'interno di grandi sistemi sanitari. Virnich ha anche ringraziato Shah per i suoi contributi, tra cui la guida di TOI nei suoi primi anni come società pubblica e il miglioramento delle capacità di reporting, conformità e analisi.
Carter ha dichiarato che è un onore diventare il prossimo CFO di TOI e che crede nella crescita e innovazione futura dell'azienda. Fondata nel 2007, TOI offre cure oncologiche specialistiche basate sul valore in contesti comunitari, servendo oltre 1,8 milioni di pazienti con 126 clinici impiegati e più di 700 collaboratori in oltre 70 sedi cliniche.
El Instituto de Oncología (NASDAQ: TOI) ha anunciado una transición de CFO. Mihir Shah, el actual CFO, dejará la organización el 14 de octubre de 2024. Rob Carter, Vicepresidente Senior de Finanzas, será promovido a Director Financiero. Carter, quien se unió a TOI en 2021, aporta más de una década de experiencia en liderazgo financiero en instituciones de salud destacadas.
El CEO Dr. Daniel Virnich expresó su entusiasmo por la promoción de Carter, citando su experiencia en oncología y en grandes sistemas de salud. Virnich también agradeció a Shah por sus contribuciones, incluido el liderazgo de TOI en sus primeros años como empresa pública y la mejora de las capacidades en reportes, cumplimiento y análisis.
Carter declaró que es un honor convertirse en el próximo CFO de TOI y su creencia en el crecimiento e innovación futura de la empresa. TOI, fundada en 2007, ofrece atención especializada y basada en el valor para el cáncer en entornos comunitarios, atendiendo a más de 1.8 millones de pacientes con 126 clínicos empleados y más de 700 compañeros en más de 70 ubicaciones clínicas.
온콜로지 연구소(NASDAQ: TOI)가 CFO 변경을 발표했습니다. 현재 CFO인 미히르 샤는 2024년 10월 14일에 조직을 떠날 예정입니다. 롭 카터, 재무 고위 부사장이 최고 재무 책임자로 승진합니다. 2021년 TOI에 합류한 카터는 주목할 만한 의료 기관에서 10년 이상의 재무 리더십 경험을 가지고 있습니다.
CEO인 다니엘 비르니치 박사는 카터의 승진에 대해 기쁨을 표하며, 그의 암 치료 및 대형 의료 시스템에 대한 경험을 언급했습니다. 비르니치 박사는 또한 TOI를 상장된 회사로서 초기 몇 년 동안 이끌어주고, 보고, 준수, 분석 능력을 향상시킨 샤에게 감사를 전했습니다.
카터는 TOI의 다음 CFO가 되는 것을 영광으로 생각하며 회사의 미래 성장과 혁신에 대한 믿음을 표현했습니다. 2007년에 설립된 TOI는 지역 사회 환경에서 전문화된 가치 기반 암 치료를 제공하며, 126명의 고용된 클리닉 의사와 700명 이상의 팀원과 함께 180만 명 이상의 환자를 서비스하고 있습니다.
L'Institut d'Oncologie (NASDAQ: TOI) a annoncé une transition de CFO. Mihir Shah, l'actuel CFO, quittera l'organisation le 14 octobre 2024. Rob Carter, Vice-Président Principal des Finances, sera promu Directeur Financier. Carter, qui a rejoint TOI en 2021, apporte plus d'une décennie d'expérience en leadership financier dans des institutions de santé notables.
Le PDG Dr. Daniel Virnich a exprimé son enthousiasme à propos de la promotion de Carter, notamment en mentionnant son expérience en oncologie et dans les grands systèmes de santé. Virnich a également remercié Shah pour ses contributions, y compris la direction de TOI pendant ses premières années en tant qu'entreprise publique et l'amélioration des capacités en matière de rapports, de conformité et d'analytique.
Carter a déclaré qu'il était honoré de devenir le prochain CFO de TOI et qu'il croyait en la croissance future et l'innovation de l'entreprise. TOI, fondée en 2007, délivre des soins spécialisés et basés sur la valeur en oncologie dans des environnements communautaires, servant plus de 1,8 million de patients avec 126 cliniciens employés et plus de 700 membres d'équipe dans plus de 70 localisations cliniques.
Das Onkologie-Institut (NASDAQ: TOI) hat einen wechsel des CFO angekündigt. Mihir Shah, der aktuelle CFO, wird die Organisation am 14. Oktober 2024 verlassen. Rob Carter, Senior Vice President für Finanzen, wird zum Chief Financial Officer befördert. Carter, der 2021 zu TOI gestoßen ist, bringt über ein Jahrzehnt an Führungserfahrung im Finanzbereich aus namhaften Gesundheitseinrichtungen mit.
CEO Dr. Daniel Virnich äußerte sich begeistert über Carters Beförderung und hob seine Erfahrung in der Onkologie sowie bei großen Gesundheitssystemen hervor. Virnich dankte auch Shah für dessen Beiträge, darunter die Leitung von TOI in den frühen Jahren als börsennotiertes Unternehmen und die Verbesserung der Fähigkeiten in den Bereichen Berichterstattung, Compliance und Analyse.
Carter erklärte, es sei eine Ehre für ihn, der nächste CFO von TOI zu werden, und sein Vertrauen in das zukünftige Wachstum und die Innovation des Unternehmens. TOI, gegründet im Jahr 2007, bietet spezialisierte, wertbasierte Krebsversorgung in Gemeinschaftseinrichtungen und betreut über 1,8 Millionen Patienten mit 126 angestellten Kliniken und mehr als 700 Teamkollegen an über 70 Klinikstandorten.
- Promotion of experienced internal candidate Rob Carter to CFO position
- Smooth transition plan for CFO role
- Company's growth to over 70 clinic locations
- Serving a population of over 1.8 million patients
- Departure of current CFO Mihir Shah
Rob Carter promoted to Chief Financial Officer
CERRITOS, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), today announced that Chief Financial Officer, Mihir Shah, will transition out of the organization effective October 14, 2024, to pursue other opportunities. Rob Carter, Senior Vice President of Finance at TOI, will be promoted to Chief Financial Officer.
Mr. Carter brings over a decade of finance leadership experience across several notable healthcare institutions. Mr. Carter joined TOI in 2021, and is responsible for corporate finance, FP&A and investor relations. Prior to joining TOI, Mr. Carter oversaw financial planning and analysis at Hoag Health System. Prior to that, he served in various financial leadership roles at Kaiser Permanente, SCAN Health Plan, and McKesson.
Dr. Daniel Virnich, Chief Executive Officer at TOI, commented, “I’m excited to announce the promotion of Rob to the role of Chief Financial Officer. He brings a wealth of experience in both oncology and large health systems, has been instrumental to our finance operations over the last several years, and is the right leader for the next phase of TOI’s growth.”
Dr. Virnich added, “I want to thank Mihir for his many contributions to TOI. Over the past two and a half years he has led us through our early years as a public company and significantly improved our capabilities around reporting, compliance, and analytics as well as a number of other critical capabilities in finance and accounting. On behalf of the whole team, we wish him the best in his future endeavors.”
Mr. Carter commented, “I’m honored by the opportunity to serve as the next CFO for The Oncology Institute. I believe we have an incredible amount of growth and innovation ahead of us, and I look forward to continue working closely with Dan and the rest of our leadership team to ensure we are delivering value to our patients and payor partners every day.”
About The Oncology Institute
Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of over 1.8 million patients including clinical trials, transfusions, and other services traditionally associated with the most advanced care delivery organizations. With nearly 126 employed clinicians and more than 700 teammates in over 70 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.
Investors
Solebury Strategic Communications
investors@theoncologyinstitute.com
FAQ
Who is the new CFO of The Oncology Institute (TOI)?
When will the CFO transition at The Oncology Institute (TOI) take place?
How many clinic locations does The Oncology Institute (TOI) currently have?
What is the stock symbol for The Oncology Institute?
